InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: tarvacin post# 195586

Thursday, 10/30/2014 2:30:31 PM

Thursday, October 30, 2014 2:30:31 PM

Post# of 346012
and it was not too long ago after Sept 7 2012 that many felt that Peregrine should have waited, instead of shouting from the rooftops early on.

The way Peregrine is playing it now is mums the word and stay as conservative as possible and save the best for last and save up multiple consecutive lineups of great PR's to spoil the fun for the shorts during each PR roll out. Charts can be made to look a certain way for us and charts can also be made to look a certain way for a signal to shorts to throw more cash in to short it down.... when all of a sudden... BAMM : )

As for saving the best for partnership talks, I see nothing wrong with that strategy. Each time an offer is made you pull up the latest stats and show them what is really under the Tustin hood.

Fiduciary Duty is maximizing shareholder value for the longterm, not the short term and not for any one specific individual or group.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News